We also showed that we can customize the SmiRNPs by switching the EGF ligand to either FGF1 or VEGF‐A, which also showed gene silencing efficacies in two different cancer cell types (colorectal carcinoma and pancreatic ductal adenocarcinoma). This evidence concerns the gene FGF1 and colorectal carcinoma.